Indegene Limited share price
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizat…Read more
- Market Cap₹ 14,409 Cr.
- Current Price₹ 598.30
- High / Low₹ 627 / 414
- Stock P/E36.0
- Book Value₹ 130
- Dividend Yield0.38 %
- ROCE15.3 %
- ROE13.90 %
- Face Value₹ 2.0
More figures (10)
- EPS (TTM)₹ 16.60
- Price / Book4.59
- OPM14.2 %
- Debt / Equity0.05
- Sales growth (4Y)15.0 %
- Profit growth (4Y)14.7 %
- Promoter holding55.5 %
- EV / EBITDA22.1
- Beta0.75
- All-time high₹ 736
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| INDGN | +4.38% | +17.10% | +22.31% | +14.96% | +10.83% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Indegene Limited is in the Health Information Services industry (Healthcare), with a market value of ₹14,409 crore.
- It trades at 36.0 times its last 12 months' earnings and 4.6 times book value.
- Revenue grew 15.0% a year over the last 4 years, profit 14.7% a year.
- Return on equity was 13.9% and return on capital employed 15.3% in the latest year.
- Debt was 0.05 times shareholders' equity.
- The share price is 4.6% below its 52-week high and up 10.8% over one year.
- Promoters and insiders hold about 55.5%; institutions about 26.9%.
Pros
AI- Strong return on equity: 20.3% on average over the last 3 years.
- Company is almost debt-free (debt is 0.05 times equity).
- Institutional (FII + DII) holding has risen by 11.0 points over 9 quarters.
Cons
AINo standout weaknesses in the reported figures.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Indegene Limited
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
- Employees
- 4,687
- Head office
- Bengaluru
- NSE industry
- Healthcare
Peer comparison
HealthcareHealthcareHealth Information Services
Part ofNifty Microcap 250
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Indegene | 598.30 | 36.0 | 14,409 | 0.38 | 116 | -0.17 | 1,063 | 39.73 | 15.3 | 13.9 | 4.59 | 14.2 | 0.05 | 55.45 | 3,511 | 15.0 |
| 2. | Inventurus Knowledge Solutions | 1,731.40 | 38.7 | 29,046 | 0.00 | 194 | 31.08 | 894 | 23.44 | 29.6 | 31.4 | 10.35 | 28.4 | 0.27 | 70.98 | 3,194 | 45.8 |
| 3. | Sagility | 45.30 | 21.4 | 21,206 | 0.44 | 217 | 18.75 | 1,963 | 25.18 | 12.5 | 10.3 | 2.16 | 17.8 | 0.11 | 50.95 | 7,193 | 19.5 |
| 4. | Fabtech Technologies | 130.30 | 10.6 | 579 | 0.45 | 4 | — | 75 | 10.26 | 11.8 | 12.9 | 1.19 | 7.7 | 0.17 | 71.97 | 411 | 28.3 |
| Median: 4 Co. | 364.30 | 28.7 | 17,807 | 0.41 | 155 | 18.75 | 978 | 24.31 | 13.9 | 13.4 | 3.38 | 16.0 | 0.14 | 63.22 | 3,352 | 23.9 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
No separate related-party filing among the recent announcements of the company.
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| 2,590 | 2,839 | 3,511 | 3,813 | |
| YOY Sales Growth % | 9.64% | 23.64% | ||
| 2,084 | 2,305 | 2,892 | 3,175 | |
| Employee Cost % | 64% | 64% | 63% | 62% |
| Other Expenses % | 17% | 17% | 20% | 21% |
| Operating Profit | 505 | 534 | 619 | 638 |
| OPM % | 20% | 19% | 18% | 17% |
| 76 | 107 | 72 | 79 | |
| Exceptional items | 2 | -20 | -20 | |
| Interest | 49 | 22 | 19 | 22 |
| Depreciation | 76 | 80 | 126 | 149 |
| Profit before tax | 459 | 539 | 525 | 526 |
| 27% | 25% | 24% | 24% | |
| Current tax | 126 | 149 | 176 | |
| Deferred tax | -4 | -17 | -52 | |
| 337 | 407 | 401 | 401 | |
| Profit to shareholders | 345 | 401 | 299 | |
| YOY Profit Growth % | 20.79% | -1.38% | ||
| EPS in Rs | 15.19 | 17.15 | 16.72 | 16.71 |
| Dividend Payout % | 12% |
Compounded Sales Growth
- TTM:
- 30%
Compounded Profit Growth
- TTM:
- -8%
Stock Price CAGR
- 1 Year:
- 11%
Return on Equity
- 4 Years:
- 22%
- Last Year:
- 14%
| ₹ Cr | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| 1,046 | 1,094 | 1,221 | 1,306 | |
| YOY Sales Growth % | 4.59% | 11.61% | ||
| 878 | 913 | 973 | 1,034 | |
| Employee Cost % | 72% | 69% | 65% | 64% |
| Other Expenses % | 12% | 14% | 15% | 15% |
| Operating Profit | 168 | 181 | 248 | 272 |
| OPM % | 16% | 17% | 20% | 21% |
| Other Income | 50 | 90 | 78 | 80 |
| Interest | 7 | 6 | 9 | 10 |
| Depreciation | 31 | 26 | 36 | 40 |
| Profit before tax | 181 | 239 | 281 | 302 |
| 24% | 24% | 25% | 25% | |
| Current tax | 44 | 63 | 71 | |
| Deferred tax | -2 | -6 | -1 | |
| 138 | 181 | 212 | 227 | |
| YOY Profit Growth % | 31.47% | 16.88% | ||
| EPS in Rs | 6.22 | 7.64 | 8.83 | 9.44 |
| Dividend Payout % | 23% |
Compounded Sales Growth
- TTM:
- 20%
Compounded Profit Growth
- TTM:
- 17%
Stock Price CAGR
- 1 Year:
- 11%
Return on Equity
- 4 Years:
- 22%
- Last Year:
- 14%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 44 | 44 | 48 | 48 |
| Reserves | 1,019 | 1,385 | 2,568 | 3,091 |
| 503 | 490 | 102 | 144 | |
| Long term borrowings | 394 | 333 | ||
| Short term borrowings | 70 | |||
| 638 | 627 | 609 | 1,337 | |
| Trade payables | 73 | 118 | 93 | 181 |
| Current liabilities | 489 | 611 | 565 | 1,086 |
| Total Liabilities | 2,204 | 2,546 | 3,326 | 4,620 |
| 152 | 121 | 139 | 206 | |
| Gross block | 305 | 303 | 139 | 454 |
| Accumulated depreciation | 153 | 248 | ||
| Goodwill & intangibles | 519 | 531 | 543 | 1,618 |
| CWIP | 6 | 4 | 12 | |
| 2,046 | 2,425 | 3,184 | 4,403 | |
| Trade receivables | 520 | 556 | 632 | 770 |
| Cash & equivalents | 74 | 189 | 241 | 301 |
| Current assets | 1,449 | 1,791 | 2,530 | 2,618 |
| Total Assets | 2,204 | 2,546 | 3,326 | 4,620 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 130 | 508 | 442 | 651 | |
| Profit for the year | 266 | 337 | 407 | 401 |
| Working capital changes | -216 | 96 | 24 | 146 |
| Direct taxes paid | -108 | -125 | -160 | -148 |
| -893 | -327 | -683 | -512 | |
| Fixed assets purchased | -19 | -11 | -30 | -44 |
| Investments purchased | -500 | -1,705 | -7,074 | -3,928 |
| Investments sold | 11 | 1,534 | 6,484 | 4,171 |
| 333 | -66 | 288 | -83 | |
| Proceeds from borrowings | 394 | |||
| Repayment of borrowings | -18 | -7 | -403 | |
| Interest paid | -18 | -32 | -10 | |
| Dividends paid | -48 | |||
| Net Cash Flow | -430 | 114 | 47 | 56 |
| Free Cash Flow | 111 | 497 | 412 | 606 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 25.0% | 27.0% | 20.1% | 13.9% |
| ROCE | — | 23.0% | 26.1% | 20.2% | 15.3% |
| Operating margin | — | 14.6% | 16.8% | 16.0% | 14.2% |
| Net margin | — | 11.5% | 13.0% | 14.3% | 11.4% |
| Debt / equity | — | 0.47 | 0.34 | 0.04 | 0.05 |
| Current ratio | — | 2.96 | 2.93 | 4.48 | 2.41 |
| Debtor days | — | 82 | 78 | 81 | 80 |
| Working capital days | — | 152 | 166 | 253 | 159 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- FIIs 9.91%
- DIIs 8.74%
- Public 81.34%
| % | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 3.79% | 4.82% | 5.03% | 5.24% | 10.05% | 11.30% | 11.48% | 10.27% | 9.91% | |
| Foreign portfolio investors (Cat. I) | 3.66% | 4.72% | 4.83% | 5.03% | 9.69% | 10.84% | 11.22% | 10.11% | 9.71% |
| Foreign portfolio investors (Cat. II) | 0.13% | 0.10% | 0.20% | 0.21% | 0.35% | 0.46% | 0.26% | 0.16% | 0.21% |
| 3.84% | 3.17% | 3.98% | 4.96% | 7.20% | 6.96% | 8.07% | 8.30% | 8.74% | |
| Mutual funds | 2.31% | 1.64% | 1.64% | 2.65% | 3.37% | 3.07% | 4.40% | 4.70% | 5.28% |
| Insurance companies | 0.27% | 0.11% | 0.10% | 0.04% | 0.01% | 0.01% | 0.01% | 0.01% | 0.02% |
| Banks | 0.02% | 0.02% | |||||||
| Alternative investment funds | 1.24% | 1.40% | 2.24% | 2.27% | 3.82% | 3.87% | 3.65% | 3.58% | 3.44% |
| 92.37% | 92.01% | 90.99% | 89.80% | 82.75% | 81.74% | 80.45% | 81.44% | 81.34% | |
| Retail (up to ₹2 lakh) | 5.94% | 5.50% | 8.39% | 7.68% | 9.69% | 9.65% | 8.83% | 8.45% | 8.35% |
| HNIs (above ₹2 lakh) | 18.73% | 18.82% | 18.02% | 3.66% | 3.82% | 3.63% | 3.62% | 4.11% | 4.14% |
| NRIs | 11.40% | 11.50% | 11.67% | 4.54% | 4.60% | 4.60% | 4.56% | 4.63% | 4.60% |
| Bodies corporate | 3.98% | 4.05% | 4.59% | 4.24% | 6.07% | 5.23% | 4.99% | 5.87% | 5.95% |
| No. of Shareholders | 2,03,599 | 1,51,440 | 1,53,789 | 1,44,708 | 1,51,997 | 1,51,809 | 1,47,182 | 1,42,119 | 1,38,533 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Indegene
No single fund or institution holds more than 1%.
As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 5.28% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- Resignation of Director/KMP/SMPIndegene Limited has informed the Exchange about Resignation of Director/KMP/SMP15-Oct-2026
- ResignationIndegene Limited has informed the Exchange regarding Resignation of Mr Mark Francis Dzialga as Non- Executive Director of the company w.e.f. October 29, 2026.15-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201808-Oct-2026
- Allotment of SecuritiesIndegene Limited has informed the Exchange regarding allotment of 16110 securities pursuant to ESOP Scheme 2020 of the Company08-Oct-2026
- Press ReleaseIndegene Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Indegene Digital Summit 2026 - National Constitution Center, Philadelphia".06-Oct-2026
- Trading WindowIndegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Press ReleaseIndegene Limited has informed the Exchange regarding a press release dated September 23, 2026, titled "From Promise to Performance: Life Sciences Leaders Focus on Operationalizing…23-Sep-2026
- Amalgamation/MergerIndegene Limited has informed the Exchange about Amalgamation/Merger of Indirect Wholly Owned Subsidiaries of the Company in Germany10-Sep-2026
- Pendency of Litigation(s)/dispute(s) or the outcome impacting the CompanyIndegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company31-Aug-2026
- Pendency of Litigation(s)/dispute(s) or the outcome impacting the CompanyIndegene Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company19-Aug-2026
- Change in Director(s)Indegene Limited has informed the Exchange regarding Change in Director(s) of the company.17-Aug-2026
- Shareholders meetingIndegene Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 13, 2026. Further, the company has informed the Exchange regarding v…17-Aug-2026
Annual reports
Credit ratings
None filed recently.
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet30-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet08-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet19-Aug-2026
- General UpdatesIndegene Limited has informed the Exchange about the Transcript of the 28th Annual General Meeting held on August 13, 202617-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet14-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet12-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Schedule of meet12-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Transcript06-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesIndegene Limited has informed the Exchange about Link of recordings31-Jul-2026
- Investor PresentationIndegene Limited has informed the Exchange about Investor Presentation30-Jul-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 31 Jul 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Resignation of Director/KMP/SMPIndegene Limited has informed the Exchange about Resignation of Director/KMP/SMPNSE filing · 15-Oct-2026
- ResignationIndegene Limited has informed the Exchange regarding Resignation of Mr Mark Francis Dzialga as Non- Executive Director of the company w.e.f. October 29, 2026.NSE filing · 15-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 08-Oct-2026
- Allotment of SecuritiesIndegene Limited has informed the Exchange regarding allotment of 16110 securities pursuant to ESOP Scheme 2020 of the CompanyNSE filing · 08-Oct-2026
- Press ReleaseIndegene Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Indegene Digital Summit 2026 - National Constitution Center, Philadelphia".NSE filing · 06-Oct-2026
- Trading WindowIndegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Press ReleaseIndegene Limited has informed the Exchange regarding a press release dated September 23, 2026, titled "From Promise to Performance: Life Sciences Leaders Focus on Operationalizing…NSE filing · 23-Sep-2026
- Amalgamation/MergerIndegene Limited has informed the Exchange about Amalgamation/Merger of Indirect Wholly Owned Subsidiaries of the Company in GermanyNSE filing · 10-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Indegene Limited
What is the share price of Indegene Limited today?
What is the market cap of Indegene Limited?
What is the P/E ratio of Indegene Limited?
Is Indegene Limited a good investment?
How can I buy Indegene Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.